Claims
- 1. A biodegradable dual-release drug delivery device, comprising:
a) a central core comprising a first bioactive agent, and b) a first layer disposed around the central core comprising a second bioactive agent and a biodegradable polymer, whereby, upon placement in a biological environment, the second bioactive agent is released, thereby resulting in sustained release of the first bioactive agent.
- 2. The device of claim 1, wherein release of the second bioactive agent renders the first layer porous.
- 3. The device of claim 1, wherein the first layer further comprises a water-soluble component that dissolves upon placement in a biological environment, thereby rendering the first layer porous.
- 4. The device of claim 1, further comprising a water-soluble second layer disposed around the first layer.
- 5. The device of claim 4, wherein the second layer comprises a third bioactive agent, which may be the same or different from the first and second bioactive agents.
- 6. The device of claim 4, wherein the second layer comprises a water-soluble polymer.
- 7. The device of claim 1, wherein the first and second bioactive agent are the same.
- 8. The device of claim 1, wherein the device is a cylindrical millirod.
- 9. The device of claim 1, wherein at least one of the first and second bioactive agents is an anti-cancer agent.
- 10. The device of claim 1, wherein the water-soluble component comprises a water-soluble polymer.
- 11. The device of claim 1, wherein the core comprises an excipient.
- 12. The device of claim 1, wherein the water-soluble component comprises water-soluble inclusions.
- 13. The device of claim 10, wherein the water-soluble component comprises crystals of a biocompatible salt or sugar.
- 14. The device of claim 1, wherein the device provides local delivery of the bioactive agent(s).
- 15. The device of claim 1, wherein the first layer comprises a polymer selected from polylactic acid (PLA) and poly(lactic-glycolic acid) (PLGA).
- 16. The device of claim 1, wherein the bioactive agent(s) comprise an analgesic agent, anti-cancer agent, antiinflammatory agent, anti-fungal agent, anti-viral agent, cell transport/mobility impending agent, beta-blocker, immunological response modifier, peptide or protein, heat shock protein, steroidal compound, neuroprotectant, antibiotic, antibacterial, antiallergenic, anti-inflammatory, decongestant, miotic and anti-cholinesterase, angiogenesis inhibitor, permeability enhancer, or mydriatic.
- 17. The device of claim 1, wherein the first bioactive agent is released at a therapeutically effective concentration for at least two days.
- 18. The device of claim 17, wherein the first bioactive agent is released at a therapeutically effective concentration for at least a week.
- 19. A method of administering a bioactive agent to a patient, comprising implanting into a patient a device of claim 1.
- 20. A biodegradable drug delivery device, comprising:
a) a central core comprising a first bioactive agent, b) a first layer disposed around the central core, comprising a water-soluble component and a biodegradable polymer, and c) a water-soluble second layer comprising a second bioactive agent disposed around the first layer, whereby, upon placement in a biological environment, the second bioactive agent is released and the water-soluble component dissolves rendering the first layer porous, thereby resulting in sustained release of the first bioactive agent.
- 21. The device of claim 20, wherein the second layer comprises a water-soluble polymer.
- 22. The device of claim 20, wherein the first and second bioactive agent are the same.
- 23. The device of claim 20, wherein the device is a cylindrical millirod.
- 24. The device of claim 20, wherein at least one of the first and second bioactive agents is an anti-cancer agent.
- 25. The device of claim 20, wherein the water-soluble component comprises a water-soluble polymer.
- 26. The device of claim 20, wherein the core comprises an excipient.
- 27. The device of claim 20, wherein the water-soluble component comprises water-soluble inclusions.
- 28. The device of claim 27, wherein the water-soluble component comprises crystals of a biocompatible salt or sugar.
- 29. The device of claim 20, wherein the device provides local delivery of the bioactive agent(s).
- 30. The device of claim 20, wherein the first layer comprises a polymer selected from polylactic acid (PLA) and poly(lactic-glycolic acid) (PLGA).
- 31. The device of claim 20, wherein the bioactive agent(s) comprise an analgesic agent, anti-cancer agent, antiinflammatory agent, anti-fungal agent, anti-viral agent, cell transport/mobility impending agent, beta-blocker, immunological response modifier, peptide or protein, heat shock protein, steroidal compound, neuroprotectant, antibiotic, antibacterial, antiallergenic, anti-inflammatory, decongestant, miotic and anti-cholinesterase, angiogenesis inhibitor, permeability enhancer, or mydriatic.
- 32. The device of claim 20, wherein the first bioactive agent is released at a therapeutically effective concentration for at least two days.
- 33. The device of claim 33, wherein the first bioactive agent is released at a therapeutically effective concentration for at least a week.
- 34. A method of administering a bioactive agent to a patient, comprising implanting into a patient a device of claim 21.
- 35. The method of claim 19 or 34, wherein the device comprises an anticancer agent and is placed at the site of a thermoablated tumor.
- 36. The method of claim 19 or 34, wherein the device comprises an analgesic agent and is placed at the site of a wound.
- 37. The method of claim 19 or 34, wherein the device comprises an antibiotic or antifungal agent and is placed at the site of an infection.
- 38. A method for manufacturing a biodegradable drug delivery device, comprising:
a) providing a central core comprising a first bioactive agent, and b) disposing a layer around the central core, the layer comprising a second bioactive agent, a water-soluble component, and a biodegradable polymer.
- 39. A method for manufacturing a biodegradable drug delivery device, comprising:
a) providing a central core comprising a first bioactive agent and an excipient, b) disposing around the central core a first layer comprising a water-soluble component and a biodegradable polymer, and c) disposing around the first layer a water-soluble second layer comprising a second bioactive agent.
Parent Case Info
[0001] This application is based on U.S. Provisional Applications No. 60/374,643, filed Apr. 23, 2002, and No. 60/326,939, filed Oct. 4, 2001, the specifications of which are hereby incorporated by reference in their entirety.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60374643 |
Apr 2002 |
US |
|
60326939 |
Oct 2001 |
US |